Correction: Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study

Correction: Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study

Saved in:

Bibliographic Details
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2022-10-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/10/10/e004223corr1.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study
by: Michael Smith, et al.
Published: (2022-03-01)

Real world study on efficacy and safety of surufatinib in advanced solid tumors evaluation
by: Hui-Ping Yan, et al.
Published: (2025-05-01)

T cells in the microenvironment of solid pediatric tumors: the case of neuroblastoma
by: Enrico Maggi, et al.
Published: (2025-02-01)

Efficacy and safety of serplulimab in solid tumors: a meta-analysis
by: Peimeng Shen, et al.
Published: (2025-06-01)

Safety and pharmacokinetics of veliparib extended‐release in patients with advanced solid tumors: a phase I study
by: Theresa L. Werner, et al.
Published: (2018-06-01)

Deciphering T-cell exhaustion in the tumor microenvironment: paving the way for innovative solid tumor therapies
by: Reshmi Nair, et al.
Published: (2025-04-01)

Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment
by: Irene Scarfò, et al.
Published: (2017-08-01)

Phase I Study of Sorafenib Combined with Gemcitabine and Carboplatin in Patients with Advanced Solid Tumors
by: Daphne W. M. Voogd, et al.
Published: (2025-05-01)

Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial
by: Mirella Nardo, et al.
Published: (2025-02-01)

Crosstalk Between the Intratumoral Microbiota and the Tumor Microenvironment: New Frontiers in Solid Tumor Progression and Treatment
by: Qing Zhou, et al.
Published: (2024-11-01)

Advances in the regulation of macrophage polarization by the tumor microenvironment
by: Minzhi Peng, et al.
Published: (2025-08-01)

Efficacy and safety of immune checkpoint inhibitors rechallenge in advanced solid tumors: a systematic review and meta-analysis
by: Jiahui Cao, et al.
Published: (2024-12-01)

Correction: Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study
Published: (2020-10-01)

Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors
by: Jeanne Tie, et al.
Published: (2020-10-01)

The solid tumor microenvironment and related targeting strategies: a concise review
by: Yingliang Wang, et al.
Published: (2025-03-01)

Correction: The effect of resveratrol, curcumin and quercetin combination on immuno-suppression of tumor microenvironment for breast tumor-bearing mice
by: Chenchen Li, et al.
Published: (2025-06-01)

Ferroptosis in the tumor microenvironment: mechanisms, advances, and therapeutic perspectives
by: Weijuan Gao, et al.
Published: (2025-08-01)

Tumor suppressor genes in the tumor microenvironment
by: Bahareh Tabanifar, et al.
Published: (2025-03-01)

Systematic review of combinations of targeted or immunotherapy in advanced solid tumors
by: Mustafa Khasraw, et al.
Published: (2021-07-01)

Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors
by: Howard Streicher, et al.
Published: (2022-03-01)

Efficacy and safety of Sacituzumab govitecan in solid tumors: a systematic review and meta-analysis
by: Yaping Zhang, et al.
Published: (2025-06-01)

Predicting immunotherapy efficacy in endometrial cancer: focus on the tumor microenvironment
by: Liubov A. Tashireva, et al.
Published: (2025-01-01)

Inflammation in the Tumor Microenvironment
by: Qing Lin, et al.
Published: (2018-01-01)

Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study
by: James L Gulley, et al.
Published: (2020-10-01)

Phase 1, open-label, multicenter, dose escalation safety and tolerability study of oncolytic virus OVV-01 in advanced solid tumors
by: Yan Wang, et al.
Published: (2025-06-01)

Constitutive IL-7 signaling promotes CAR-NK cell survival in the solid tumor microenvironment but impairs tumor control
by: Robin Parihar, et al.
Published: (2025-07-01)

Advances in the role and mechanisms of tumor microenvironment in colorectal cancer metastasis
by: CHEN Guanchi，CUI Long
Published: (2025-07-01)

Role of tumor microenvironment in ovarian cancer metastasis and clinical advancements
by: Yang Wang, et al.
Published: (2025-05-01)

Recent advances in novel tumor immunotherapy strategies based on regulating the tumor microenvironment and immune checkpoints
by: Hanhui Jing, et al.
Published: (2025-06-01)

First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors
by: David Turner, et al.
Published: (2025-08-01)

Development and validation of a UPLC-MS/MS method for the quantification of parsaclisib and its application to pharmacokinetics and metabolic stability studies
by: Chenjian Zhou, et al.
Published: (2025-07-01)

Meta-analysis on the safety and efficacy of Erdafitinib in treating FGFR1–4 mutated solid tumors
by: Jiyu Huang, et al.
Published: (2025-08-01)

Phase I study on neoadjuvant combination immunotherapy with mogamulizumab and nivolumab for solid tumors
by: Takashi Kojima, et al.
Published: (2025-04-01)

A phase I study of the CDK4/6 inhibitor ribociclib combined with gemcitabine in patients with advanced solid tumors
by: Aurora Norman, et al.
Published: (2025-01-01)

Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors
by: Douglas E Feltner, et al.
Published: (2025-07-01)

Phase II study evaluating the safety and efficacy of neratinib and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors: KCSG AL20‐17/KM23 trial
by: Kyoungmin Lee, et al.
Published: (2025-07-01)

Tumor Microenvironment: Lactic Acid Promotes Tumor Development
by: Yuting Gao, et al.
Published: (2022-01-01)

Editorial: The tumor microenvironment and immunotherapy for head and neck tumors
by: Yifan Jiang, et al.
Published: (2025-06-01)

Emerging immunotherapy and tumor microenvironment for advanced sarcoma: a comprehensive review
by: Hai Huang, et al.
Published: (2025-05-01)

T cell subsets in cervical cancer tumor microenvironment: advances and therapeutic opportunities
by: Weilin Guo, et al.
Published: (2025-06-01)